Genetic predictors of severe skin toxicity in stage III colon cancer patients treated with cetuximab: NCCTG N0147 (Alliance)

BACKGROUND: Cetuximab, an epidermal growth factor receptor inhibitor used to treat multiple cancer types including colon cancer, causes severe skin toxicity in 5-20% of patients, leading to decreased quality of life and treatment delays. Our understanding of which patients have an increased risk of...

Descrizione completa

Salvato in:
Dettagli Bibliografici
Pubblicato in:Cancer Epidemiol Biomarkers Prev
Autori principali: Labadie, Julia D., Hua, Xinwei, Harrison, Tabitha A., Banbury, Barbara L., Huyghe, Jeroen R., Sun, Wei, Shi, Qian, Yothers, Greg, Alberts, Steven R., Sinicrope, Frank A., Goldberg, Richard M., George, Thomas J., Penney, Kathryn L., Phipps, Amanda I., Cohen, Stacey A., Peters, Ulrike, Chan, Andrew T., Newcomb, Polly A.
Natura: Artigo
Lingua:Inglês
Pubblicazione: 2020
Soggetti:
Article
Accesso online:https://ncbi.nlm.nih.gov/pmc/articles/PMC7909617/
https://ncbi.nlm.nih.gov/pubmed/33203692
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/1055-9965.EPI-20-1274
Tags: Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !

Documenti analoghi